

CORPORATE NEWS

MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de

MeVis' profitability further increased in the first quarter

Further improvements in earnings with slightly declining sales

- Consolidated sales declined in the first three months as expected, by 9% to €3.3 million (prev. year: €3.6 million)
- Maintenance business contribution further increased to 47 % (prev. year: 42 %)
- Earnings before interest and taxes (EBIT) up to € 0.8 million (prev. year: €0.6 million)
- Consolidated net profit increased significantly to € 0.8 million (prev. year: €0.1 million)
- Liquidity stable at €8.6 million (December 31, 2012: €8.7 million)

Bremen, May 16, 2013 – Today, MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software provider for the medical imaging market, announced its results for the first quarter of 2013.

As expected sales in the first quarter of 2013 came to €3,318 k, down 9 % on the first quarter of 2012 (€3,637 k). While license sales declined by 21 % to €1,589 k (prev. year: €2,011 k), due in part to a package of LungCAD licenses in the Other Diagnostics segment in the first quarter of 2012, maintenance and service revenues again rose by 4 % to €1,568 k (prev. year: €1,513 k).

Group sales as expected down by 9% year on year, maintenance business continues to grow

Sales in the Digital Mammography segment went up slightly by 1 % to €2,673 k (prev. year: €2,650 k). In contrast, sales in the Other Diagnostics segment declined by 35 % to €645 k (prev. year: €987 k).

Capitalized development expenses were lowered considerably by 41 % year on year to €410 k (prev. year: €691 k).

Operating costs were again significantly reduced in the first quarter of 2013. As personnel expenses amounted to €1,949 k, thus being 15 % down on the prior-year quarter. Other operating expenses also decreased to €484 k, corresponding to a 20 % reduction year on year.

Cost-cutting measures further increase operative profitability

After depreciation and amortization of € 495 k (44 % down year on year), and due to the ongoing cost-cutting measures, EBIT (earnings before interest and taxes) could be improved considerably to € 806 k (up a significant 30 % on the prior-year figure of € 622 k). The EBIT margin increased to 24 % (prev. year: 17 %).

EBIT significantly stronger than the same quarter last year, now 24 % margin

An improvement in the financial result from € -90 k in the previous year to € 102 k in the first quarter of 2013, results in pre-tax earnings in the reporting period of € 908 k (prev. year: € 532 k). Taking into account lower income tax expenses of € 106 k MeVis closed the first quarter of the current financial year with a consolidated net profit of € 802 k (prev. year: € 108 k). Thus earnings per share amount to € 0.47 (prev. year: € 0.06).

Consolidated net profit of € 0.8 million

Liquid funds remained stable in the reporting period and amounted to € 8,622 k on March 31, 2013 (December 31, 2012: € 8,665 k).

Group liquidity stable at € 8.6 million

"On account of business development in the first three months of 2013, we confirm our forecast for the current fiscal year, which expected sales in 2013 to be down slightly on the 2012 fiscal year. In our opinion the consolidated earnings before interest and taxes (EBIT) is mainly influenced the expected slight drop in sales, the lower level of capitalized development expenses and the again slight reduction in personnel expenses. Overall, we expect EBIT to decline slightly." says Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG. „In addition, we expect a positive cash flow again in 2013, where in addition to the ongoing business the reduction in trade receivables should make a significant contribution."

Forecast for 2013 confirmed

"We now focus on the development and implementation of measures to generate future sales growth so as to offset the trend of a declining new license business." added Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. "The expansion of business relationships with existing industrial customers is showing initial signs of success, which are expected to materialize into small contributions to sales in the second half of the year. We have also had initial talks with potential new industrial customers to gain additional customers in our core business of selling software licenses and therefore to modify and expand our product portfolio to meet the needs of our customers. In order to build up the business with Internet-based services, we will launch initial services on the market this year and gradually expand these services. "

Growth with existing and new industrial customers as well as via new sales channels

The financial reports of the company can be downloaded here:

http://www.mevis.de/ir_finanzberichte.html

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.